Eli Lilly 2009 Annual Report Download - page 34

Zyprexa, our top-selling product, is a treatment for schizophrenia, acute mixed or manic episodes
associated with bipolar I disorder, and bipolar maintenance. Zyprexa sales in the U.S. increased 6 percent
in 2009, due to higher prices, partially offset by reduced demand. Sales outside the U.S. increased
4 percent driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates.
Demand outside the U.S. was favorably impacted by the withdrawal of generic competition in Germany in
early 2009.
Sales of Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral
neuropathic pain, generalized anxiety disorder, and fibromyalgia, increased 13 percent in the U.S., driven
by higher prices and increased demand. Sales outside the U.S. increased 18 percent, driven by increased
demand, partially offset by the unfavorable impact of foreign exchange rates and lower prices.
Sales of Humalog, our injectable human insulin analog for the treatment of diabetes, increased 20 percent
in the U.S., driven by higher prices, increased demand, and wholesaler buying patterns. Sales outside the
U.S. increased 3 percent, driven by increased demand, partially offset by the unfavorable impact of foreign
exchange rates.
Sales of Alimta, a treatment for various cancers, increased 45 percent in the U.S., primarily driven by
increased demand. Sales outside the U.S. increased 50 percent, driven by increased demand, partially
offset by the unfavorable impact of foreign exchange rates. Demand outside the U.S. benefited from the
addition of the non-small cell lung cancer indication in Japan.
Our sales of Cialis, a treatment for erectile dysfunction, increased 16 percent in the U.S., driven by higher
prices, increased demand, and wholesaler buying patterns. Sales outside the U.S. increased 3 percent,
driven by increased demand and to a lesser extent, higher prices, partially offset by the unfavorable
impact of foreign exchange rates.
Sales of Gemzar, a product approved to treat various cancers, increased 2 percent in the U.S., due
primarily to higher prices. Sales outside the U.S. decreased 37 percent, driven by reduced demand and
lower prices as a result of the entry of generic competition in most major markets, and to a lesser extent,
the unfavorable impact of foreign exchange rates.
Sales of Evista, a product for the prevention and treatment of osteoporosis in postmenopausal women and
for reduction of risk of invasive breast cancer in postmenopausal women with osteoporosis and postmeno-
pausal women at high risk for invasive breast cancer, decreased 3 percent in the U.S., driven by reduced
demand, partially offset by higher prices. Sales outside the U.S. decreased 7 percent, driven by the
outlicensing of Evista in most European markets and, to a lesser extent, lower prices.
Sales of Humulin, an injectable human insulin for the treatment of diabetes, increased 6 percent in the
U.S., due primarily to higher prices, partially offset by reduced demand. Sales outside the U.S. decreased
9 percent, driven by the unfavorable impact of foreign exchange rates and, to a lesser extent, lower prices,
partially offset by increased demand.
Sales of Forteo, an injectable treatment for osteoporosis in postmenopausal women and men at high risk
for fracture, increased 6 percent in the U.S., driven by higher prices, partially offset by reduced demand.
Sales outside the U.S. increased 3 percent, driven by increased demand and prices, partially offset by the
unfavorable impact of foreign exchange rates.
Sales of Strattera, a treatment for attention-deficit hyperactivity disorder in children, adolescents, and
adults, increased 2 percent in the U.S., driven by higher prices, partially offset by reduced demand. Sales
outside the U.S. increased 15 percent, driven by increased demand and higher prices, partially offset by
the unfavorable impact of foreign exchange rates.
Worldwide sales of Byetta, an injectable product for the treatment of type 2 diabetes, increased 6 percent
to $796.5 million during 2009. We report as revenue our 50 percent share of Byetta’s gross margin in the
U.S., 100 percent of Byetta sales outside the U.S., and our sales of Byetta pen delivery devices to Amylin.
Our revenues increased 13 percent to $448.5 million in 2009.
We report as revenue for Erbitux, a product approved to treat various cancers, the net royalties received
from our collaboration partners and our product sales. Our revenues were $390.8 million in 2009,
compared with $29.4 million in 2008. We acquired Erbitux as part of our acquisition of ImClone in
November 2008.
Animal health product sales in the U.S. increased 25 percent, primarily driven by the inclusion of Posilac
sales following the acquisition completed October 2008. Sales outside the U.S. decreased 4 percent, driven
primarily by the unfavorable impact of foreign exchange rates.
Gross Margin, Costs, and Expenses
The 2009 gross margin increased to 80.6 percent of total revenue compared with 78.5 percent for 2008.
This increase was due to the impact of changes in foreign currencies compared to the U.S. dollar on
22
FORM 10-K